Sigma Planning Corp Boosts Stock Position in Liquidia Co. (NASDAQ:LQDA)

Sigma Planning Corp lifted its stake in Liquidia Co. (NASDAQ:LQDA) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,210 shares of the company’s stock after acquiring an additional 2,115 shares during the period. Sigma Planning Corp’s holdings in Liquidia were worth $767,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Catalina Capital Group LLC boosted its stake in Liquidia by 6.5% in the 4th quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock worth $215,000 after purchasing an additional 1,125 shares during the period. DMC Group LLC lifted its holdings in shares of Liquidia by 17.4% in the fourth quarter. DMC Group LLC now owns 16,302 shares of the company’s stock worth $192,000 after buying an additional 2,419 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Liquidia by 3.5% in the fourth quarter. Rhumbline Advisers now owns 80,652 shares of the company’s stock worth $948,000 after buying an additional 2,741 shares in the last quarter. Walleye Trading LLC grew its stake in Liquidia by 54.7% during the third quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after acquiring an additional 4,670 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Liquidia by 43.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,708 shares of the company’s stock worth $187,000 after acquiring an additional 5,669 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Stock Down 2.8 %

LQDA opened at $15.45 on Wednesday. The business’s fifty day simple moving average is $13.67 and its 200 day simple moving average is $11.69. Liquidia Co. has a 52 week low of $8.26 and a 52 week high of $16.99. The stock has a market cap of $1.31 billion, a PE ratio of -9.48 and a beta of 0.27.

Analyst Ratings Changes

Several brokerages have commented on LQDA. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of Liquidia in a report on Thursday, January 9th. Wells Fargo & Company started coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $25.38.

Insider Transactions at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $73,613.22. Following the completion of the sale, the insider now owns 270,388 shares of the company’s stock, valued at $3,185,170.64. This represents a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the transaction, the general counsel now owns 573,478 shares in the company, valued at $6,755,570.84. The trade was a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 73,945 shares of company stock worth $874,403. 30.10% of the stock is currently owned by corporate insiders.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).